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Abstract  
Some scientists avoid the work with experimental animals. For that, it is important to describe alternative 
methods. In this review, some bioassays were described as an alternative for the experimental animals. The 
concept of cancer formation was discussed to show why such bioassays are useful for detecting antitumor 
compounds. The bioassays described in this review are technical, practical and recommended as a preliminary 
screening of large samples for the existences of antitumor activities. Such bioassays could reduce the pain of the 
experimental animals.  
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1. Introduction  
Cancer is an expression of cellular diseases! 
Cancer equals death! After the treatment of 
tuberculosis, cancer is one of the major human 
killers [1]. The actual first steps in 
understanding this cell disease started at the 
time when the oncogenic viruses were 
discovered. Oncogenic viruses enable in lab 
tumor induction with a clear mechanism. Now 
we understand that cancer is a result of 
modifications were happening in the cells' 
genetic materials that transform normal cell to 
malignant. The unique criterion of the cancer 
cell is that, it has macromolecules similar to the 
normal cell's macromolecules. Although the 
malignant cell's attitude/structure is abnormal, 
the immune system recognizes it as a normal 
cell. Cancer cell differs quantitatively rather 
than qualitatively from normal cells. But, 
cancer can be detected by abnormal growth, 
pains and pressure on the surrounding tissue. 
They cause a drop in the function of the tissues 
or organs and uncomfortable feel of the break 
caused in many vital biopathwayes. How 
selectively can we inhibit one cell and leave 
another if they are similar in their 
macromolecules building blocks? There are 
many articles discussing different concepts 
about cancer [2-9].  
Hanahan and Weinberg (2000) suggested that 
six essential alterations in the cell physiology 
collective direct malignant growth: 1) 
self-sufficiency in growth signals, 2) 
insensitivity to growth-inhibiting (antigrowth) 
signals, 3) evasion of programmed cell death 
(apoptosis), 4) limitless replicative potential, 5) 
sustained angiogenesis, and 6) tissue invasion 
and metastasis [10]. These criteria are the 
major and a unique feature of cancer cell. For 
more details, refer to Hanahan and Weinberg 
(2000) [10]. Hanahan and Weinberg (2011) 
added two additional factors: reprogramming 
of energy metabolism and invading immune 
destruction [11]. Amara (2011) suggests two 
other major criteria, that cancer cell still 
qualitatively similar to normal cell and can 
escape from the immune system and that some 
DNA change or damage should be happening to 
change the normal cells into tumor cells [12]. 
Amara (2012) has discussed in details the 
heredity roles as well as genes and food 
interaction with cancer elevation [13]. Also, 
pathogen such as an oncogenic virus (infect 
human and animals) or Agrobacterium (infect 
plant) can cause cancer directly by causing a 
direct impairing/or change in the genetic 
materials to favour cancer formation [12-20].  
This review will not include experimental 
animal or human study except that describe the 
preparation of the microsomes from the rates' 
livers. It will contain protocols about some 
simple bioassays. Perhaps if we succeeded to 
simplify the concept of the cancer to the public 
they can take some critical protection steps. 
"Protection is usually better than treatment". A 
normal cell is a cell in correct form, which 
grows, multiplies and performs its biological 
functions accurately, collaborating and 
communicating with other cells in the 
surrounding tissue and organ perfectly and has 
a correct chromosome number/structures. It has 
programs for cell growth, multiplication, death, 
metabolism, DNA repair mechanisms, 
extra-protocol for self-damage and death 
(apoptosis) which prompt when there is a need. 
Cancer cell in contrast grows, multiplies and 
does its biological function inaccurately, 
collaborating and communicating with other 
cells in the surrounding tissues and organs in a 
wrong way. It has defected programs for cell 
growth, uncontrolled multiplication, abnormal 
metabolism, defect DNA repairing mechanisms 
and corrupted apoptosis. Moreover, it can grow 
out of its place (tissue or organ) and can pass 
through the blood vessels and initiate cancer in 
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other tissues and organs (metastasize). The 
major problem in the cancer cell is that its 
growth is uncontrollable and it is undetectable 
by the immune system [11]. So, cancer 
treatment in most cases is based on cytotoxic 
drugs. Being toxic, they suppress the immune 
system (immunosuppressant) with different 
levels [21]. Correct DNA will give correct 
protein. Correct protein will do correct 
function(s). If not, the problems will start and 
as a result, probably cancer can be elevated 
directly or indirectly based on the damage rate 
in the cell macromolecules/biopathwayes. Thus, 
cancer is a cell disease and its start point 
happened in the DNA. “Cancer is a sudden (in 
case of oncogenic viruses or strong mutagen) 
or accumulative change (mutations) in a 
specific gene(s) or in the cell's genetic 
materials which cause an irregular 
uncontrolled growth and multiplication which 
can lead to the death of the host but not the 
death of cancers' cells (whenever there are 
nutrients, oxygen etc.)”.  
Tumors have different types, structures and 
names. A tumor is a swelling (L. tumere = to 
swell). Tumor means a mass of abnormal, 
independently growing tissue. Alternatively 
tumors are called neoplasms (Gr. neos = new; 
plasm = formation or substance). Neoplasms 
can be benign (remain in situ and unable to 
invade other tissues) or can be malignant (grow 
fast, uncontrolled and able to invade other 
organs and tissues to localize a new tumor 
(metastasize). Malignant neoplasms may be 
carcinomas (Gr. Karkinos = crab) or 
epitheliomas (Both are epithelial in origin) or 
sarcomes (connective and supporting tissues or 
striated muscles) or leukemia (involves cells of 
the lymphatic system) [22]. The term cancer is 
broadly used to mean any or all malignant 
neoplasms.  
How Cancer does take place? There are three 
main routes of cancer: through heredity, DNA 
Cracker and mutagens [11]. An endogenous or 
exogenous factor that can affect the normal cell 
and transform it into a cancer cell is a 
cancer-causing agent. A fit individual can be 
genetically free from any of the inheriting 
problems. However, being fit does not mean 
that the genetic materials are accurate. This is 
because of the presence of two alleles, one on 
each chromosome. Each can contain one copy 
of a particular gene. Therefore, if one gene has 
been impaired, the other correct one (in the 
second allele) can recover its function. This is 
based on the similarity between both genes. 
There are many mechanisms and possibilities to 
transfer cancers' causing or initiating genes 
(oncogenic genes) or causative factors from 
generation to generation. These possibilities 
include: each parent has one defect gene, so the 
newborn gains the two defected genes, and born 
with cancer. Alternatively, only one parent has 
one defect gene (the newborn will gain only one 
gene from a parent) and the newborn can 
recover this defect by the existence of the other 
inherited correct gene. This is an important 
example can clarify many facts about cancer. 
After some time, it is possible that a change in 
the correct gene can be happened and it cannot 
be able to recover the deficiency in the already 
inherited defect one anymore (or defect due to 
other factors such as the environmental factors). 
At that stage, the cancer risk probably can be 
happened. This simply explained the Knudson's 
model [23]. One should consider which gene(s) 
is/are become(s) defected. Defects in many 
genes could not elevate cancer but can support 
its formation side by side with other criteria. 
This proves that our genome and the genomes 
of other creatures are subjected to continuous 
modification and repair. Healthy genes could 
protect against cancer formation. The heredity 
plays a major role in that [13]. Cancer can be 
transmitted by direct infection in both of 
animals and plants. For animals, the oncogenic 
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virus is a causative agent for cancer. As a 
simpler mechanism (could be understood) in 
plant, Agrobacterium tumefaciences cause a 
unique form of cancer called crown gall [24-25]. 
Those causative agents can name "Crackers", 
while they can crack the genomic DNA and 
transform a normal cell to a cancer cell [11]. 
Out of the hereditary rulers and the DNA 
cracking rules; ionizing radiations, ultraviolet 
light, various chemical substances such as 
methylchalanthrene, smoke from wood, cool 
and vegetable leaves, automobile exhaust,  
cresols and a certain level of mechanical 
irritants and so on, can cause or lead to cancer. 
These agents, physical and chemical, are 
collectively called mutagens [22]. Mutagens 
are often said to be oncogenic (Gr. onkos = 
mass or swelling). Inefficient or damaged 
endogenous antioxidant systems cannot protect 
us from the side effects of both of catabolism 
and anabolism processes or the active 
endogenous oxidant system [26, 27]. Stress on 
the cell(s)/organ(s), abnormal life style, 
alcohols, cigarettes, or even our food, will be 
converted finally to oxidants and free radicals 
able to attack our DNA. A sharp balance 
between oxidants and antioxidant amounts is 
critical for healthy life [26]. When does cancer 
start? In addition, how much time it needs to be 
spread? The change in the cell's DNA, which 
modifies it to a cancer cell, can be happened at 
any time based on the cell type, the amount and 
the body response for its causative agents. It 
can be happened in one-step as a direct effect of 
a strong mutagen, or after a short time but 
enable accumulating sufficient mutations until 
the formation of a true cancer cell. 
Alternatively, it can start so early in the genome 
of the ancestors within the same ancestry. In 
fact, the time can be short, moderate or longer 
until the constituents of the cancer formation 
criteria have been satisfied. The different kind 
of the defence mechanisms can elongate the 
time for cancer formation or can completely 
protect against it. The DNA repairing system is 
able to correct many of the DNA damage but it 
cannot be able to do correction after a certain 
level of damage. The damage can attack the 
DNA repairing genes themselves. If the damage 
happened in an essential gene in the DNA 
repairing system, it will not be able to do its 
function and the cell will lose an important 
chance for surviving. A cell has a self-killing 
strategy in case of DNA mistakes. If such 
mechanism (apoptosis) is impaired, a corrupted 
cell could divide and cancer could be formed. 
The damage can be irreversible or hardly 
corrected, but it can be recovered if there is an 
extra correct copy of the same gene(s) as in 
case of the existence of a second allele.  
 
2. Cancer treatment 
To protect ourselves from macromolecules 
damaging agents, balanced food, correct 
lifestyle and healthy environment should be 
available [26]. However, if a normal cell is 
transformed into a cancer cell and multiplies 
into a correct cancer structure; the treatment 
must start soon. Surgery is the first aid and 
should be used whenever it is possible. 
Radiotherapy is usually used after surgery and 
in some cases can stand-alone. However, if 
surgery and radiotherapy could not cure cancer, 
antitumor compounds should be used before 
metastasize.  
 
2.1. Cytotoxic drugs 
A successful antitumor compound is the one, 
which could kill or incapacitate cancer cells 
selectively. This is not usually the fact. Until 
now, there is no real ideal single antitumor 
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compound, which could distinguish between 
cancer cells and normal cells. They are usually 
toxic chemicals with great side effects. They 
could kill cancer cells in a faster rate than the 
normal cells (Except of the rapidly dividing 
cells such as those of the gut mucosa, the hair 
follicles, the bone marrow, the germinal 
epithelium of the testes, the thymus, and the 
fœtus where they have a high division rate.  
 
2.2. Alkylating agent 
Alkylating agents are compounds that have 
strongly electrophylic chemical reactions 
through forming carbonium ion intermediate or 
of transition complexes with the target 
molecules (proteins, RNA and DNA) [28]. 
Alkylating agents, including the nitrogen 
mustards, are able to arrest cell division mainly 
by alkylation via cross-linking guanine bases in 
DNA. They kill the cancer cells by causing a 
tangle of strands of DNA rather than by 
interfering with its formation. The affected 
cells are prevented to divide because the DNA 
strands cannot be separated and duplicated. 
2.3. Antimetabolites 
Several effective drugs interfere with the 
formation of purines and pyrimidines in the 
DNA [29, 30].  
2.4. Immunotherapy 
Immunotherapy may be used in three main 
ways in the treatment of neoplastic disease. 
2.4.1. Immunostimulants 
Attempts were made to increase the general 
level of immunological responsiveness by 
administration of adjuvant (e.g. BCG vaccine, 
Corynebacterium parvum, Vaccinia vaccnia, or 
extracts of yeast cells). Some success was 
achieved in experimental animals in which the 
frequency of induced tumors was reduced. 
Drugs such as levamisole that stimulates the 
immune mechanisms provide another possible 
means of non-specific stimulation’s. Active 
immunization with malignant cells is achieved 
by killing tumor cells by irradiating them in 
vitro before re-injecting them. The antigenicity 
is remains and a degree of immunity to living 
tumor cells is imparted. Passive immunity may 
be transmitted by transferring serum, 
lymphocytes or bone marrow from an animal, 
which was immunized against proteins of 
human bladder cancer [31, 32]. 
2.4.2. Lymphokines 
Lymphokines are peptides produced by 
lymphocytes that regulate the immune system 
and mobilize defences against foreign invaders 
including bacterial and viral infections [1]. 
2.4.3. Antibodies 
2.4.3.1. Polyclonal antisera 
The polyclonal antisera are antibodies resulting 
from injecting animals with the appropriate 
antigen for large production of antibodies. The 
specificity of the antibody can vary quite 
markedly, because large molecules and cells are 
in themselves a collection of different antigens, 
each of which may elicit an antibody 
production. Each antibody may be produced in 
different amounts, and they may bind to their 
corresponding antigen with different degrees of 
affinity [33].  
2.4.3.2. Monoclonal antibodies 
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The monoclonal antibody has a greater antigen 
specificity, homogeneity and availability, 
produced by a clone, or colony of cells that 
drive from white blood mother 
cell-B-lymphocyte and so are identical. When 
an antigen stimulates them to manufacture an 
antibody, they all make the same one. Their 
advantage comes from their high specificity for 
the antigen produced in vitro, and their 
homogeneity. Hybridomes between cancer cells 
and these immunized lymphocytes can be used 
as a continues source for monoclonal 
antibodies. Leukopheresis machine, a 
blood-cell separator, takes about four hours to 
separate red from white blood cells, re-infuse 
the red cells immediately, and then isolates five 
to ten billion white blood cells (leukocytes) in a 
plastic bag. These leukocytes (potential killer 
cells) were then incubated with monoclonal 
antibodies that would instruct them to attack 
cancer cells. This mixture can be intravenously 
infused into the patient who over one to two 
hours can go back home on the same day [33]. 
2.5. Hormones differentiation and 
growth factors 
The growth rate of some tumors is influenced 
by changes in their hormonal environment. In 
that respect, carcinoma of the prostate, breast, 
ovary and uterus are influenced by the sex 
hormones. In addition, the leukemia and 
reticuloses are affected by corticosteroids; a 
group of steroid hormones has an important 
role in the therapy of these neoplasms. 
Moreover, hormones such as androgens; 
namely testosterone propionate, calusterone, 
fluxymesterone; used in the treatment of 
advanced carcinoma of the breast. Estrogens; 
namely diethylistilbesal; used in the treatment 
of carcinoma of the prostate, while progestation 
agents; namely medroxy-progesterone acetate 
or hydroxy-progesterone caproate are used in 
the treatment of endometrial carcinoma. 
Adreno-corticosteroid is used in the treatment 
of acute leukemia in children and malignant 
lymphomas [21,34]. 
2.6. Miscellaneous groups 
2.6.1. Antibiotics 
Antibiotics are substances produced by bacteria 
as secondary metabolites. They are produced in 
large scale by a fermentation process, 
synthetically or semi-synthetically. It is 
important to highlight that biological derived 
compound including antibiotics and other 
compounds which are livo rotator is safer than 
synthetic ones which can contain Dextro rotator 
configuration (as contaminants). In the body, 
these agents may inactivate the two strands of 
DNA or interfere with the duplication of DNA 
needed for cell division. Actinomycin D, 
daunorbicin, mithramycin, mitomycin C 
[35,36] and bleomycin [37,38] all used in the 
treatment of cancer because of their effect on 
DNA replication; for example actinomycin D 
and daunorubicin bind to DNA and prevent its 
replication [39]. 
2.6.2 Enzymes 
L-asparaginase can be used in the treatment of 
cancer. Certain neoplastic tissues, including 
acute lymphoblastic leukemia cells requires an 
exogenous source of the amino acid 
L-asparaginase. It was observed that injected 
malignant lymphoma cells failed to survive in 
the guinea pig, and that guinea pig serum 
prevented the survival of lymphoma cells 
injected into mice. The explanation laid on the 
fact that the guinea pig serum contains the 
enzyme L-asparaginase that destroys the amino 
acid L-asparagine, which is needed for forming 
  
Amro A. Amara. American Journals of Cancer Science 2013, 1:33-59 Page 8 of 27 
Ivy Union Publishing | http: //www.ivyunion.org March 11, 2013 | Volume 1 | Issue 1  
nucleic acids. L-asparaginase catalyzes the 
hydrolysis of L-asparagine to aspartic acid and 
ammonia, thus preventing the malignant cell to 
uptake the asparagine available from the 
extracellular fluid [40]. 
2.7. Medicinal plants 
Plant is the main source for human drugs 
[41-46]. Scientists are concerned with 
investigating medicinal plants, which are 
commonly used in conventional medicine 
[47-49]. Dubick (1986) reported that the 
medical use of herbs is deeply rooted in human 
history and built-in into the historical medicine 
of merely all human cultures [49]. He describes 
the history of Ginseng and Garlic as two well 
known plants broadly used –till now- in 
conventional medicine. Some famous selected 
examples used to represent the importance of 
those plants are based on human observation, 
trial and error, religious advices and from 
various generations' accumulated experiences. 
They should never be neglected or classified as 
unscientifically based treatment [49, 50]. The 
number of the medicinal plant-derived from 
traditional medicine is huge. Vinca rosea [51], 
Podophyllum peltatum [52] and Taxus spp [53] 
are selected examples. These plants and many 
others led to the discover of important drugs 
including vincristine, vinblastine, 
podophyllotoxin, 10-hydroxy-camptothecin 
and taxol [53, 54]. There are a huge number of 
antitumor compounds derived from plants 
source and includes: Terpenes, Monoterpenes 
[55], Sesquiterpenes [56-58], Miscellaneous 
sesquiterpenes [56-57], Gemacrenolides [59], 
Guaianolides and Pseudoguaianloides [56], 
Elemanoids, Diterpenes [60-61], Simaroublide 
(Quasinoids) [56], Cucurbitacin [56], 
Withanalides [56], Cardenolides [61], Lignans 
[63], Alkaloide; Diterpene [63], Pyrralizidine 
[56], Isoquinoline [64,65], Benzo (C) 
phanathridine [66], Berberines [67], 
Phenanthroidalizidine and 
Phenanthroquinolizidine [56], Taxus [68], 
Acronycine [68], Comptothecine [69], 
Cephalotaxus [70], Bisindol [35], 
Indoloquinone [71], Colchicine [56], 
Ellipticine [72], Emetine [56], Amaryllidaceae 
[56] Flavonoids [73], Protein and Short 
peptides. Many other forms are included too. It 
is important to highlight that some of the 
purified plant derivatives can promote cancer, 
such as Azoxyderivatives and some crude 
extracts [50].  
3. Antitumor bioassay 
3.1. Inevitability of biological test 
It is important to investigate that the discovery 
of a new antitumor compound is not that an 
easy task. One plant can contain thousands of 
active constituents but few of them, one or none 
has/have anticancer activities. Crude extracts, 
which show antitumor activity upon 
purification, could loss such activity. Moreover, 
a compound could be less effective in its pure 
form. It could loss some of its activities if exist 
alone (purified). Therefore, Amara et al. (2008) 
suggest using crude extracts in cancer treatment, 
especially when derived from active edible 
plants. Edible plants prove historically to be 
safe and have medical effects. They are 
subjected to a real clinical trial over thousands 
of years and prove to be safe. Every portion of 
the plant and every fraction of the extract must 
be tested biologically before any of its 
constituents is isolated and characterized. 
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Usually only those fractions which show 
biological activities are a subject for further 
studies and purification [50]. Some of the plant 
material shows either synergism or antagonism.  
Only biological bioassays could determine that 
a compound has antitumor activity. However, 
one should consider that a single antitumor 
compound can be active with one and more 
cancer but not with all. The filler of one 
bioassay to prove that one or mixed compound 
has/have antitumor activities is not an absolute 
result. This compound(s) could show antitumor 
activities with other bioassays based on the 
differences between the compounds mode of 
actions and the bioassay sensitivity and 
specificity. 
3.2. Toxicity 
For experts, the toxicity of particular plant or 
plant extract(s) means the existence of 
physiological active constituent(s). This is not 
a general rule. Edible plants, which nearly have 
no toxicity, have promising antitumor 
constituents and were recommended by many 
authors [50]. Meanwhile, the investigation of 
the existence of toxicity is a crucial step for 
detecting active compounds. Using small 
organisms like Brine shrimp (BS) for toxicity 
determination has some advantage especially if 
one can correlate the toxicity to the antitumor 
activity. BS is reliable, inexpensive, in house 
and cost effective. This is due to using less 
amount of the tested compound(s), less lab 
space, short time and so on. 
3.2.1. BS toxicity test 
BS (Artemia salina L.) bioassay can be used as 
a preliminary screening for the presence of 
active constituent including the antitumor 
compounds and it is used to determine the plant 
extract toxicity [74]. Using BS larvae, 
pharmacognosists and natural product chemists 
were able to detect and isolate plant 
constituents and active compounds with a 
variety of pharmaceutical activities [75, 76]. 
BS is considered rapid, inexpensive, in-house 
bioassay for screening and fractionation 
monitoring of physiologically active plant 
extracts [77]. It was used also to determine the 
toxicity of: organophosphates [78], mycotoxins 
[79], anesthetics [80], morphine-like 
compounds [80], antibacterial and antifungal 
[82, 83] active compounds from marine 
environments [84] and many others [85,98]. 
According to Meyer et al. (1982) several 
extracts derived from natural products which 
had LC50 = 1000 µg/ml using BS bioassay were 
known to contain physiological active 
principles [74]. BS bioassay can be used as 
preliminary in vitro antitumor assay while it 
has a positive correlation with 9KB (human 
nasopharyngeal carcinoma) citotoxicity and 
3PS (P388) (in vivo murine leukemia) and can 
substitute both of them [74, 99, 100].  
3.3. Cell lines 
Briefly, for in vivo screening antitumor 
compounds expensive cell lines were used like 
the 3PS (P388) (methylcholanthrene- induced) 
leukemic mouse assay and the in vitro 
screening for 9KB (human nasopharyngeal 
carcinoma) cytotoxicity [101, 102]. The most 
extensively in vivo assay employed by NCI for 
screening plant extracts since 1960 are sarcoma 
180 (SA), adenocarcinoma 755 (CA), lymphoid 
leukemia L1210 (LE), Walker 356 
carcinosarcoma (WA), and P388 lymphocytic 
leukemia (PS). The later one is still used for 
screening plant extracts. SA and CA were 
discontinued in 1962 (activity against these 
tumors were due to more animal weight loss 
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than to a direct defect on the tumor). WA was 
discontinued in 1969 because further use of 
new drugs is not appropriate without an 
assessment of the clinical value of the agents. 
Furthermore, WA proved to be highly sensitive 
to tannins and phytosterols, almost ubiquitous 
in higher plants, which have no value as new 
drugs. LE is no longer used for screening plant 
extracts but it is predictive for clinical activity 
and it has recently been used in the tumor panel. 
KB culture line derived from human 
epidarmoid carcinoma of the nasopharynx is 
thus further enhanced if it is predictive for LE 
or other tumor panel activity and not predictive 
for SA, CA and WA [103].  
3.4. Could plant tumor used for 
screening antitumor compounds? 
Why not! There are many similarities between 
plant and animal cells. Compounds that being 
able to suppress plant cancer are able to do that 
in the animal cancer. Moreover, manipulating 
plant tumor is simple, safe and less expensive 
and the used amount of the tested materials is 
cost effective. 
Based on the similarity between plant cells 
and animal cells (because they are Eukaryotic) 
plant cancer could be used as a model for 
screening antitumor compounds. A. 
tumefacienes is able to induce crown galls on 
plants such as potato. If a compound is applied 
during the crown gall (plant tumor) formation 
and shows, a suppressive effect, it might have 
an antitumor activity. Two essential parameters 
should be adjusted: the concentration based on 
the toxicity test and the existence of anti A. 
tumefacienes activity. The toxicity could be 
determined by in vivo BS toxicity test while the 
A. tumefacienes activity could be determined 
by Agar Well Diffusion technique to detect any 
antimicrobial activity existed in the used 
compound(s) or crud extract [50]. Extracts 
show antimicrobial activity against A. 
tumefacienes should not be used. Alternatively, 
if in a lower concentration, the antimicrobial 
activity was lost; such concentration could be 
evaluated [50]. This shows the importance of 
the correct determination of the used quantities 
and their type of effect. The antimicrobial 
activity compound could be used in 
concentration unable to kill A. tumefacienes 
[50].  
3.4.1. A. tumefaciens and plant tumor 
Crown gall is a plant neoplastic disease induced 
by the gram-negative bacterium A. tumefaciens 
[24]. A. tumefaciens cause serious plant 
infections with more than sixty dicotyledon 
families and many gymnosperms lead to great 
damages [24]. Agrobacterium species are the 
only known organisms capable of interkingdam 
gene transfer. Agrobacterium can initiate tumor 
formation on most dicotyledonous and some 
monocotyledonous species [104]. Such tumors 
do not require the continuous presence of 
bacteria for proliferation [105]; this means that 
the infected plant was transformed genetically. 
The factors required for tumor formation 
(T-DNA) are encoded on a large 
tumor-inducing (Ti) plasmid. The T-DNA is 
imported into plant cells and integrated into the 
host chromosomal DNA, resulting in genetic 
manipulation of the host. The expression of 
T-DNA genes in the host cell results in the 
production of enzymes that catalyze the 
synthesis of plant hormones, which are 
responsible for tumor growth and the formation 
of novel amino-acid-sugar conjugates, termed 
opines. As opines can serve as carbon and 
sometimes nitrogen sources for Agrobacterium 
which lead to the exclusion of most other 
microorganisms, they provide a selective 
advantage for these species [106]. Under 
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laboratory conditions, normally recalcitrant 
plants [107-110], and even human cells [111] 
can be transformed by the Agrobacterium. The 
interaction between the Agrobacterium and 
plant cells can contain several steps including 
host recognition, virulence (Vir) gene 
expression, attachment to the host cell, 
targeting of Vir factors and T-DNA into the host 
cell, and chromosomal T-DNA integration. On 
chemical recognition of plant-derived 
compounds, the Agrobacterium Vir gene 
expression is induced and followed by the 
physical interaction between the bacterium and 
the plant cells. Bacterial transfer machinery is 
subsequently produced and assembled to 
import Vir factors into the host cell. Once 
inside the plant cell, the T-DNA is translocated 
into the nucleus, in which it integrates into the 
host chromosome. On the expression of T-DNA 
genes, plant cells are re-programmed for tumor 
growth and production of opines. The A. 
tumefaciens infection symptoms resemble 
tumor in mammalian cells. The tumor 
formation starts when bacterial cell transfer 
part of the Ti (tumor-inducing) plasmid to the 
infected plant cell genome [24, 112]. The 
validity of potato disc bioassay is predicated on 
the observation that certain tumorigenic 
mechanisms are similar in plants and animals 
like multiplying rapidly without apoptosis 
[113]. Several modifications in the original 
potato disc antitumor protocol (as described by 
Favus et al. (1977)) were performed by Galsky 
and Wilsey, (1980) and Galsky et al. (1981a, b) 
which show that the crown gall tumor can be 
inhibited on potato (Solanum tuberosum L.) 
tuber discs with an apparent correlation with 
compounds and extracts derived from plants 
known to be active with 3PS (in vivo, murine 
leukemia) [114-117]. A. tumefaciens potato 
disc tumor bioassay (AtPDT) was used to 
evaluate the ethanol and hexane extracts of 
seeds of 41 Euphorbiaceae species. The 
inhibition of 20% or more of the tumors is 
considered significant [54, 99, 118]. Coker et al. 
(2003) proved that camptothecin, palitaxel, 
vinblastine, vincristine and podophyllin have 
significant inhibitory effects on crown gall 
induced tumor. Potato disc bioassay proved to 
be critical in investigating many purified 
compounds, new plant constituents as well as 
crude plant extracts [50, 54, 119].  
3.4.1.1. Collection of plant materials  
The plant different materials should be 
collected from a known and trusted suitable 
source. It can represent any part of a healthy 
plant or any kind of its products (Latex, gum, 
etc.). They should be fresh, newly collected and 
dried. They should be correctly preserved or 
stored in the way that their main constituents 
are not affected by any biological source 
(microbes, insects, enzymes etc.), chemical 
treatment (preservatives, insecticides etc.) or 
physical changes (temperature, radiation etc.). 
Fresh plants must be dried using standard 
criteria. Plants or plants' different parts should 
not be heated up to 40
o
C (during any steps). 
After 40
o
C active constituents could be 
degraded. Any microbial or insect infection 
will give incorrect results. Glassware should be 
cleaned using standard methods. The use of 
chemicals (such as a disinfectant) could 
interfere with the results. Any process or step 
could lead to a modification in the plant 
constituents before and after the extraction 
process should be avoided. After the collection 
of the plant different materials, they were dried 
in fresh air then grounded to a powder using 
mechanical mortar (heat should be avoided 
during this process). Plants different materials 
can be stored routinely at -20°C.  
3.4.1.2. Preparation of extracts 
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Different crude extracts can be prepared 
according to Furring et al. (1982) [118]. The 
protocol based on defatting using hexane 
followed by an ethanol extraction. Other 
solvent(s) can be (of course) used [50]. The 
basis of using both of those solvents (Hexane 
and ethanol) is that hexane (non-polar solvent) 
will extract oil and fat while ethanol will 
remove the other polar constituents. So, other 
solvents, which could extract non-polar 
material, can be used in the defatting process 
and the same in case of the polar constituents. 
Solvents should be evaporated completely from 
the plant part or from the extracted constituents 
(easily and completely) without causing any 
type of change. Existing of any solvent traces 
will interfere with most of the biological 
bioassays. For re-dissolving the extract 
materials aiming to conduct biological assays 
(for crude extracts or chemicals have low 
polarity) in water, DMSO could be used. 
DMSO out of many tested solvents proves to be 
universal and less toxic.    
3.4.1.3. Extraction process 
The extraction process can be as follows: one 
hundred grams of the plant's dried material 
(after complete grinding to fine powdered 
particles) were weighted and deflated using 200 
ml hexane in a 1L Erlenmeyer flask, then 
agitated for 2 hr, at 25°C using a reciprocal 
suitable shaker at 250 rpm. This step can be 
repeated several times until the extraction was 
complete. A simple test could be determined if 
the extraction process is completed or not. This 
could be by testing one drop of the extract on 
watch glass; evaporate the solvent and test the 
transparency of the glass surface. The total 
extracted volume of each plant then subjected 
to filtration using Whatman No.1 filter paper. 
The final un-extracted portion can be dried in 
an exposed 20 cm glass Petri dish under aseptic 
condition. After complete drying, the same 
process can be repeated -as above- using 
absolute ethanol. Different extracts can be 
concentrated using a rotator evaporator at 40°C. 
The concentrated extracts then collected and 
dried using vacuum drier. Each extract was then 
transferred to l0 ml weighed, small and clean 
glass vial and the crude extract weight was 
determined. All the extracted materials can be 
preserved at -20°C.  
3.5. Bioassays 
Subsequent bioassays can be carried out to 
determine the biological activity of the plants' 
different extracts. They are mainly a toxicity 
determination bioassay for detecting the 
existence of active physiological constituents; 
antimicrobial bioassay to remove any extract 
has antimicrobial activity and a basic antitumor 
bioassay to detect the existence of antitumor 
compounds. 
3.5.1. BS assay  
The bioassay based on Artemia saline Letch., 
encysted eggs [collected freshly]. To prepare 
newly hatched BS, incubate 10 mg of the 
encysted eggs in 5 ml distilled water for 5 min 
to activate hatching. The eggs are then 
transferred in 300 ml of seawater under 
artificial light at 28°C, pH 7-8. After the 
incubation of the encysted eggs for 24 hours, 
the new hatched nauplii can be collected using 
a Pasteur pipette. Keep the nauplii for an 
additional 24 hr under the same conditions to 
reach the metanauplii stage. Preparation of 
extracts for toxicity bioassay can be carried out 
following the procedure of Meyer et al. (1982) 
with modification [74]. The percentage of 
mortality for each concentration can be 
determined from the number of dead and living 
nauplii. In the case where death occurred in the 
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control, the data are corrected using the 
following formula: % death = [(dead test- dead 
control)/10] X 100. For determining the LC50, 
prepare stock solutions representing 6.66, 
16.66, 33.33 and 66.66 mg plant extract/ml 
DMSO for each plant extract and sterilize them 
using bacterial membrane filter (0.22 µm 
diameter). Add seventy five µl from each stock 
solution completed to 4.925 ml sterilized sea 
water (using bacterial membrane filter 0.22 
µm) -in suitable glass container- to represent 
concentrations 100, 250, 500 and 1000 µg plant 
extract/ml sea water for each plant extract then 
mix well using vortex. Use three replicas of 
each concentration. Prepare the blank vials 
using filter sterilized seawater. Prepare the 
control vials using 25 µl DMSO. Transfer ten of 
48 hr old nauplii to each vial, and leave them 
for 24 hr incubation period at 28
o
C. Count the 
treated nauplii and recorded as alive or dead 
[50]. 
3.5.2. Agar well diffusion (AWD) 
antimicrobial bioassay 
Agar well diffusion antimicrobial bioassay is a 
handy tool for evaluating the presence of 
antimicrobial activity in a pure compound, a 
mixture or crude extract [50, 120-122]. The 
existence of antimicrobial activity can be 
determined using the AWD technique. In this 
method, Petri dishes were supplied with a deep 
NB medium inoculated previously with 1% A. 
tumefaciens. Punch four wells out of the agar, 
by using a clean sterile cork borer (6 mm in 
diameter). Seal the base of each hole with a 
drop of melted sterile water agar (15 g agar per 
liter H2O) using a sterile Pasteur pipette. Use 
for each plant's extract four concentration 
representing 100, 250, 500 and 1000 µg/ml to 
determine their antimicrobial effect on the A. 
tumefaciens. Pipette each concentration into 
one wall, and then incubate the plates at 4
o
C for 
4 hours to allow the extracts to diffuse into the 
medium. Incubate the plates at 28
o
C for 24 hr 
after the incubation period, measure the square 
radius of the clear zone around each well (y
2
) 
and divide over the square well radii (x
2
) to 
obtain absolute unit (AU) for the inhibition 
zone [123]. 
3.5.3. A. tumefaciens crown gall potato disc 
bioassay 
This technique was carried out according to the 
original method used by Favus et al. (1977) 
modified and improved by Galsky and Wilsey, 
(1980); Galsky et al. (1981 a, b); Ferrigni et al. 
(1982), Ferrigni and Mchaughlin (1984) and 
Amara et al. (2008) [50, 99, 114-118]. 
3.5.3.1. Preparation of A. tumefaciens 
Culture the A. tumefaciens strain routinely on 
high nutrient agar (NA) medium, consisting of 
5 g/l peptone, 3 g/l beef extract, 5 g/l glucose 
and 15 g/l agar (pH 7.0). Culture of 
experimental work was grown in the equivalent 
liquid medium at 28°C on a rotary shaker at 150 
rpm.  
Determine the viable bacteria number 
according to Stainer et al. (1986) [124]. 
Determine the absorbance calibration curve of 
the bacterial growth using a suitable 
spectrophotometer. This step is helpful to use a 
known amount of cell as well as to use the 
active cells in their log phase. Log phase 
maintains active cells and better tumor 
formation.  
3.5.3.2. A. tumefaciens-crude extract mixture 
preparation  
Dissolve 15.625 mg of each plant extract stock 
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solution in l ml DMSO and filter the mixture 
through bacterial membrane sterile Millipore 
filter (0.22 µm), and receive the filtrate into a 2 
ml sterile Ependorf tube. Add volumes of 6.4, 
16, 32 and 64 µl from the stock solution to 1.5 
ml sterile Ependorf tubes respectively and 
adjust the volume to 500 µl using sterile 
distilled water and add 500 µl of A. tumefaciens 
broth culture (10
9
 cells/ml) to each of the 
previous tubes, and then mix them well by 
gentle vortex. The different extracts at a final 
concentration represent 100, 250, 500 and 1000 
µg/ml and are calculated by the general 
formula: Plant final concentration (µg/µl) = 
[Used stock (µl) X Stock concentration (µg)]/ 
Final volume (µl). The DMSO in final 
concentration was not more than 12.5%. 
Prepare the control by adding 50 µl of filtered 
DMSO to 450 µl of sterile distilled water, and 
mix with 500 µl of the A. tumefaciens broth 
culture (10
9
 cells/ml) [50]. 
3.5.3.3. Preparation of potato discs (Tumor 
induction and antitumor screening)  
Immerse whole tubers of potato of moderate 
size for surface disinfecting in 0.5% sodium 
dichloroisocyannurate solution for 30 min, 
wash twice in sterilized distilled water. The 
potato then left to air dry for further twenty min, 
under aseptic conditions. Cut the two ends of 
the potato tuber using a sterilized sharp cutter. 
Obtain potato cylinder of 1.5 cm in diameter 
using a sterilized cork borer and then the 
cylinder is cut into discs of 0.5 cm thickness, 
after discarding 1 cm from both cylinder ends. 
Transfer three discs aseptically onto the surface 
of autoclaved water agar in 9 cm sterilized Petri 
dish, where the discs have to be inoculated 
within thirty min, with the plant 
extract-bacterium mixture. Inoculate fifty µl of 
each plant extract-bacterium mixture of each 
concentration to each potato disc. For one 
experiment, each concentration has three 
plates; each plate contains three potato discs. 
Inoculate nine discs with one concentration of 
the previous mixture. Each experiment is 
repeated three times. The Petri dishes were 
incubated at 25°C for 15-20 days. After the 
incubation period, the tumors were counted 
with the aid of a binocular after staining the 
surface of the discs with Lygol’s solution (I2 3 
g/l + KI 30g/l). 10 ml sterile distilled water can 
be added after each pleat to avoid the dryness of 
the agar. Incubating the plates at 28°C with A. 
tumefaciens from log phase will enable better 
conditions for crown galls growth after 
fourteen days which can be seen clearly with 
the naked eye (Fig. 1.). 
 
 
 
 
 
 
 
 
Figure 1 Potato disk with crown gall (Control) (a) and after treatment with plant crude extract (Inhibition) 
(B)  
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Figure 2 The BST test on Probit paper of Curcuma longa ethanolic extract  
 
3.5.3.4. Statistical analysis  
The LC50 and IC50 from each of BS or AtPDT 
can be determined manually by using Probit 
paper (Fig. 2). The best fit line is the line pass 
through most of the points. Manual fitting can 
be helpful for beginners especially for 
evaluating the accuracy of the experiment 
rather than getting the most correct line and for 
direct eye judgment. In some cases when the 
line did not pass between or through most of the 
points perfectly the experiment might be in 
need to be repeated to gain results that are more 
accurate. However, for more accurate 
determination for the LC50 and IC50, Probit 
software can be used. It conducts regression 
analysis and fit the line automatically. Data can 
be collected and entered in the personal 
computer and the LC50 and IC50 can be 
determined for BS and AtPDT bioassays 
respectively. Priprobit ver., 1.63 software can 
be used. Probit analysis estimates the log doses 
by applying a distribution model to the 
observed data, so a median effective dose LC50 
or IC50 where 50% of organisms in population 
responses can estimate relative potencies (Rho), 
between preparations. The hierarchical cluster 
analysis method can be performed by using any 
of the available statistical package software to 
analyze LC50 and IC50 derived from the results 
obtained from of BS and/or AtPDT [50]. The 
obtained different LC50 and IC50 can be further 
analyzed with a two-way ANOVA statistical 
method to determine the significant differences 
[50].  
4. Further evaluation and 
additional bioassay 
Before one jump to the animal model other 
additional experiments can be used for further 
confirming the existence of the antitumor 
compounds, such as the use of the CP450 
derived bioassays which comes from animal 
origin and need a minimum number of animals 
and test the presence of alkaloids and 
flavonoids (the major antitumor compounds) 
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[11, 125-127].  
4.1. Aryle Hydrocabon hydroxylase 
[AHH] activity and antioxidant activity 
against H2O2 production by lindane 
induced mice hepatic microsomes 
(Awney et al., 2007) 
These two protocols describe how to 
investigate the inhibitory effect of different 
plant extracts on aryl hydrocarbon B(a)p 
hydroxylase activity and the mediated H2O2 
production (as a major source of DNA oxidative 
damage in cells) in mice liver treated with 
lindane [129].  
4.1.1. Experimental Animals 
House up five mice in a cage, according to NIH 
guidelines with free access to distilled water 
and food. Chemicals: Lindane (1, 2, 3, 4, 5, 
6-hexachlorocyclohexane) 99%, 
benzo(a)pyrene (99%) and Nicotinamide 
adenine dinucleotide hydrogen phosphate 
(NADPH) and Catalase. 
4.1.2. Preparation of mice hepatic 
microsomal fraction 
Prepare liver microsomes from mice injected 
intraperitoneally with organochlorine 
insecticide (eg. Lindane) dissolved in corn oil 
(10 mg/kg) for four days. The control contains 
animals receive corn oil only. Mice were fasted 
overnight, starved after the last injection and 
sacrificed by cervical dislocation. The 
abdominal cavities were immediately opened 
and the liver was excised, weighed, and then 
washed with cold 0.1 M phosphate buffer, pH 
7.4. All the following operations were carried 
out at 4°C. The washed livers were minced with 
sterile scissors in 2 volumes of 0.25 M sucrose 
(2 ml/g wet liver), and homogenized with a 
Teflon piston using five strokes. The 
homogenate was centrifuged by a high-speed 
centrifuge for 20 min at 11,000 xg to remove 
intact cells, nuclei, and mitochondria. The 
supernatant was subsequently ultracentrifuged 
at 105,000 xg for 60 min to sediment the 
microsomal pellets. The supernatant was 
discarded and the microsomal pellets 
resuspended in 0.25 M sucrose (3 ml/10 g liver) 
and stored immediately in 1 ml aliquots at 
-70°C [130].  
4.1.3. Determination of AHH activity 
Aryl Hydrocarbon Hydroxylase activity can be 
determined by the method of Awney et al. 
(1997) with some modifications [127]. The 
reaction mixture, in a total volume of 1 ml, 
contained fifty pmoles of tris-chloride buffer, 
pH 7.4; 0.36 µmoles of NADPH; 3 µmoles of 
MgCl2/ 0.1 ml microsomes suspended in 0.1 M 
potassium phosphate buffer pH 7.4 (1 mg 
protein/ml). One hundred nmoles substrate, 
benzo(a)pyrene were added in 0.05 ml 
methanol to start the reaction. Plant extracts 
were added in 10 µg/ml. After 10 min of 
incubation at 37°C, the reaction was terminated 
by the addition of 1.0 ml cold acetone and the 
mixture was shaken with 3.0 ml hexane for 10 
min to extract the derivatives of 
benzo(a)pyrene. A 1.0 ml aliquot of the organic 
layer was extracted with 2 ml 1 N NaOH and 
the fluorescence of the NaOH extract was 
measured immediately at 396 nm excitation and 
522 nm emission by using a spectrofluorometer. 
The amount of enzyme is defined as the pmoles 
of phenolic product (equivalent to 
3-hydroxybenzo(a)pyrene formed during the 
incubation)/mg protein/min [50, 129]. The 
amount of the protein concentration in hepatic 
microsomes fraction was assayed by the 
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method of Lowry et al. (1951) (or any protein 
quantification method) using bovine serum 
albumin as a standard [131]. 
4.1.4. Determination of Microsomal 
Hydrogen Peroxide 
The hydrogen peroxide formation during the 
metabolic activation of B(a)p in the presence of 
lindane induced hepatic microsomes can be 
assayed by the method described by 
Hildebrandt (1978) [132]. Plant extract was 
added to the reaction mixture of 10 µg/ml. 
 
4.2. Screening for the presence of 
alkaloids and / or nitrogenous bases 
and flavonoids in plant extract  
The existence of alkaloids and/ or nitrogenous 
bases and flavonoids are an indication for the 
presence of antitumor constituents [11, 
133-136].  
4.2.1. Test for alkaloids and /or nitrogenous 
bases (Harborne, 1980) [137] 
Extract ten grams of the air dried powder with 
acidified water. Add 5% ammonium hydroxide 
solution to the acidic filtrate to render it to 
alkaline and then extract the mixture with 
chloroform. Collect the chloroform layer in 
another container then evaporate to dryness and 
dissolve residue in 2 ml of 10% diluted 
hydrochloric acid and test with the following 
alkaloidal reagent:  
1) Dragendorff’s reagents (solution a: 0.85 g 
bismuth subnitrate dissolved in a mixture of 10 
ml glacial acetic acid and 40 ml water; solution 
b: 8 g potassium iodide dissolved in 20 ml 
water; color reagent: mix 5 ml solution a with 5 
ml solution b, add 20 ml glacial acetic acid, 
complete to 100 ml with water).  
2) Iodoplatinate’s reagent, (solution a: 5% 
platinic chloride in water; solution b: 10% 
potassium iodide in water; color reagent: 5 ml 
solution a, 45 ml solution b, and 100 ml water 
were mixed).  
3) Mayer’s reagent (1.355 g mercury iodide, 5.0 
g potassium iodide in distilled water to make 
100 ml). An orange, violet or white precipitate 
obtained respectively indicates the presence of 
alkaloids and /or nitrogenous bases. Thin layer 
chromatography was carried out to detect the 
presence of alkaloids in the chloroform plant 
extract using solvent system Methanol: 
Chloroform (1:9) as a running solution, silica 
gel G60 Merck was used to prepare the 
chromatoplate (20 x 20 cm) which was 
activated at 110°C for 30 min. Two mg of each 
plant sample was dissolved in 0.5 ml 
chloroform, then 50 l was spotted and the 
plate was immersed in the solvent system. After 
completing the run, the plates were taken out 
from the jar, allowed to dry, and then sprayed 
either with Dragendorff’s reagent or with 
Iodoplatinate’s reagent. Orange and violet 
colors were obtained respectively indicating 
the presence of alkaloids and /or nitrogenous 
bases. Mayer's reagent will give a white 
precipitate.  
4.2.2. Tests for flavonoids (Harborne, 1980) 
[137] 
An ethanolic extract of the air dried powder of 
each plant sample was exposed to magnesium 
metal turning up to one min, and then 3 ml of 
hydrochloric acid (1%) was added, a faint 
reddish color obtained indicates the presence of 
flavonoids. One gram of the air dried powder of 
each plant sample was treated with 5 ml 1% 
hydrochloric acid solution. The sample was 
shaken while adding 5 ml drop by drop of 5% 
sodium hydroxide until a yellow color was 
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formed indicating the presence of flavonoids. 
Thin layer chromatography was carried out to 
detect the presence of flavonoids in an 
ethanolic extract of the air dried powder of each 
plant sample using solvent system acetic acid: 
water (1:1). Silica gel G60 Merck was used to 
prepare the chromatoplate, which was activated 
at 110°C for 30 min. Two mg of each plant 
sample was dissolved in 0.5 ml chloroform, 
then 50 l were spotted and the plate was 
immersed in the solvent system. After 
completing the run; the plate was taken out 
from the jar, allowed to dry and, tested under a 
UV lamp at 224 nm and 366 nm, the appearance 
of fluorescence under the UV light indicates the 
presence of flavonoids. 
4.3. Ames test 
Using microbes to detect a chemical mutagen is 
a practical approach due to simplicity. The 
existence of antitumor activities in certain 
compound or crude plant extract did not ensure 
that it is not mutagens [50]. One bacterial strain 
can grow to colonies with the same genotype on 
Petri dish; the differences in the phenotypes 
between colonies from a single microbial strain 
can be a marker for the change in their genetic 
materials. If this change is due to a mutation in 
one of the twenty amino acid producing 
pathways, the synthetic medium contains all the 
amino acids except that which will be a good 
condition to determine a second mutation 
which can recover this defect. Ames test 
becomes one of the favourite prokaryotic 
models for preliminary identifying presence of 
mutagens [105,138-143]. The Ames's scientific 
group has improved the 
Salmonella/microsomes tumorgenic test during 
years especially from 1966 to 1973 [144-145]. 
The principle of the tester strains is to use 
mutants caused by a known type of DNA 
damage (base pair substitution, and the various 
kinds of frame shift mutations) for detecting 
mutagens by the sensitive and convenient of 
one of the genes of the excision repair system 
which was introduced in all used strains. The 
strain was improved to be more sensitive to 
compound in its surrounding environment 
where its ability to produce lipopolysaccharise 
was impaired [145, 146]. The amount of used 
mutagen can be firstly estimated by the AWD 
antimicrobial bioassay as well as by the BS 
toxicity test as described in this review and the 
references within [50]. The pour plate 
technique is made by adding 0.1 ml of the tester 
strain culture to a small sterile test tube (13 x 
100 mm) that contain 2 ml of molten (45
o
C) top 
agar (which contains a trace of histidine, excess 
biotine and the appropriate volume of mutagen). 
The plate is then mixed and poured onto the 
surface of a minimal agar plate with 
Vogal-Bonner E medium [147] (1.5% agar, 2% 
glucose) until the agar hardness [146]. A 
control plate for spontaneous reversion rate 
should be done for each strain in which the 
mutagen is omitted. All plates are incubated 
upside down at 37°C for 2 days, after which the 
number of revertant colonies appearing can be 
counted. If too much of the compound is added 
so that the light known of the background and 
the spontaneous revertant are inhibited, the 
experiment should be repeated with fewer 
compounds. Aqueous solution of mutagens is 
prepared in sterile screw-cap tubes with sterile 
water or with DMSO. It is possible to add up to 
0.5 ml DMSO per plate. Top agar (0.6% Difco 
agar, 0.6% NaCl) is autoclaved. When the 
temperature becomes at nearly 45°C, 10 ml of a 
sterile solution of 0.5 mM L-histidine, HCl-0.5 
mM biotin is added; the bottle is mixed by 
gentle swirling. The agar is added to the tubes 
and allowed to equilibrate to 45°C before 
addition of any bacteria. The trace of histidine 
in the top agar allows all the bacteria on the 
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plate to undergo several divisions: this growth 
is necessary in many cases to induce the 
mutagenesis process.  The liver microsomes’ 
system can be added to the top agar (S.9 Mix). 
The S-9 mix contains per ml: 0.3 ml of S-9 
fraction, 8 mM MgCl2, 33 mM KCl, 5 mM 
glucose-b-phosphate, 4 mM TPN, and 100 mM 
sodium phosphate (pH 7.4). To 2 ml of molten 
to agar at 45°C, added 0.1 ml of the bacterial 
tester strain culture (2 to 3 x109/ml), up to 0.1 
ml of a solution (the tested compound), and 0.5 
ml of S-9 mix: then the tube is rotated quickly 
and the contents are poured on the agar plate. 
Alternatively, the tested compound can be 
added to the surface of the disc. Three sterile 
discs (filter paper) on the surface of one of the 
agar plates can be placed. Different mutagen 
can be tested using one plate and different 
discs.  
4.4. DNA /Protein binding bioassay 
Plant crude extracts active constituents might  
be able to interact with the DNA or to bind with 
it. Alkaloids are well known for their ability to 
combine with the DNA. These compounds 
(specifically the alkylating agent) can arrest the 
cancer cell’s DNA, stop many vital activities 
for their survival and finally can cause the 
cancer cell death. Spectrophotometer can be 
used to detect any shift in the DNA band due to 
linkage happened. One could design his own 
protocol by scanning the compounds in the 
different spectra.  Usually in particular 
wavelength, most components give a clear band, 
which can be used for its detection. Highly 
purified compounds can be used for performing 
standards. Differences in the 
spectrophotometric bands can be explained as a 
change happened due to binding. There are two 
possibilities if we know the test compound, 
know its spectra, we can easily compare its 
spectra before and after mixing it with the DNA. 
If its spectra show a shift or new band appears, 
this means that the compound has the ability to 
react (companied) with the DNA. Alternatively, 
the DNA spectra can be used as a template and 
the shift in its spectra after adding the 
compound mean that it is able to react with the 
DNA.  
The reaction between macromolecules and 
tested compounds can be monitored by 
different other ways such as enzyme inhibitors, 
the blocking of the DNA restriction site, shift in 
the molecular weight in the analytical gel or 
agarose gel electrophoresis, and so on [11].  
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